FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

Secukinumab becomes the only interleukin-17A inhibitor approved for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.